The Global Burden of Resistant Hypertension and Potential Treatment Options
European Cardiology Review · 19.06.2024 · 19
DOI: 10.15420/ecr.2023.51 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 19.06.2024. Verfasst von Giacomo Buso und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Division of Internal Medicine, ASST Spedali Civili Brescia, University of Brescia Brescia, Italy. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Resistant hypertension (RH) is defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) that remains ≥140 mmHg or ≥90 mmHg, respectively, despite an appropriate lifestyle and the use of optimal or maximally tolerated doses of a three-drug combination, including a diuretic. This definition encompasses the category of controlled RH, defined as the presence of blood pressure (BP) effectively controlled by four or more antihypertensive agents, as well as refractory hypertension, referred to as uncontrolled BP despite five or more drugs of different classes, including a diuretic. To confirm RH presence, various causes of pseudo-resistant hypertension (such as improper BP measurement techniques and poor medication adherence) and secondary hypertension must be ruled out. Inadequate BP control should be confirmed by out-of-office BP measurement. RH affects about 5% of the hypertensive population and is associated with increased cardiovascular morbidity and mortality. Once RH presence is confirmed, patient evaluation includes identification of contributing factors such as lifestyle issues or interfering drugs/substances and assessment of hypertension-mediated organ damage. Management of RH comprises lifestyle interventions and optimisation of current medication therapy. Additional drugs should be introduced sequentially if BP remains uncontrolled and renal denervation can be considered as an additional treatment option. However, achieving optimal BP control remains challenging in this setting. This review aims to provide an overview of RH, including its epidemiology, pathophysiology, diagnostic work-up, as well as the latest therapeutic developments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Sciences, Division of Internal Medicine, ASST Spedali Civili Brescia, University of Brescia Brescia, Italy.
- Lausanne University Hospital, University of Lausanne Lausanne, Switzerland.
Zitieren
APA
Buso, G., Agabiti-Rosei, C., Lemoli, M., Corvini, F., & Muiesan, M. L. (2024). The Global Burden of Resistant Hypertension and Potential Treatment Options. European Cardiology Review, 19. https://doi.org/10.15420/ecr.2023.51
Vancouver
Buso G, Agabiti-Rosei C, Lemoli M, Corvini F, Muiesan ML. The Global Burden of Resistant Hypertension and Potential Treatment Options. European Cardiology Review. 2024;19. doi:10.15420/ecr.2023.51
BibTeX
@article{Buso2024,
author = {Buso, Giacomo and Agabiti-Rosei, Claudia and Lemoli, Matteo and Corvini, Federica and Muiesan, Maria Lorenza},
title = {The Global Burden of Resistant Hypertension and Potential Treatment Options},
journal = {European Cardiology Review},
year = {2024},
volume = {19},
doi = {10.15420/ecr.2023.51}
}
EUVIMED